Bispecific AbTCR (Anti-CD19/CD22) T Cells

· First Affiliated Hospital Xi'an Jiaotong University

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Bispecific AbTCR (Anti-CD19/CD22) T Cells, covering 2025-09-17 to 2025-09-17. Get the full timeline:

Most recent: Clinical Trial Update: Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma [EARLY_Phase 1]